Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL

Clinical trial NCT07613788 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07613788
Sponsor: Ruijin Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Start date: 2026-05-01
Primary completion: 2028-11-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.